[go: up one dir, main page]

MX2024002581A - Lou064 para el tratamiento de la esclerosis multiple. - Google Patents

Lou064 para el tratamiento de la esclerosis multiple.

Info

Publication number
MX2024002581A
MX2024002581A MX2024002581A MX2024002581A MX2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A MX 2024002581 A MX2024002581 A MX 2024002581A
Authority
MX
Mexico
Prior art keywords
lou064
multiple sclerosis
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2024002581A
Other languages
English (en)
Inventor
Ying Zhang
Bruno Bieth
Michael Juhnke
Souvik Bhattacharya
Bruno Cenni
Karin Rapp
Kim - Hien Sin
Peter End
Gordon Graham
Rajesh Singh Karan
Allison Donna Mann
Etienne Pigeolet
Huixin Yu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2024002581A publication Critical patent/MX2024002581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a LOU064 o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento eficaz de la esclerosis múltiple (EM).
MX2024002581A 2021-09-03 2022-09-01 Lou064 para el tratamiento de la esclerosis multiple. MX2024002581A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163240444P 2021-09-03 2021-09-03
US202163282363P 2021-11-23 2021-11-23
US202263304106P 2022-01-28 2022-01-28
US202263353866P 2022-06-21 2022-06-21
US202263369008P 2022-07-21 2022-07-21
PCT/IB2022/058205 WO2023031840A1 (en) 2021-09-03 2022-09-01 Lou064 for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2024002581A true MX2024002581A (es) 2024-03-20

Family

ID=83438454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002581A MX2024002581A (es) 2021-09-03 2022-09-01 Lou064 para el tratamiento de la esclerosis multiple.

Country Status (10)

Country Link
US (1) US20240350489A1 (es)
EP (1) EP4395779A1 (es)
JP (2) JP7564347B2 (es)
KR (1) KR20240055038A (es)
AU (1) AU2022337087A1 (es)
CA (1) CA3229887A1 (es)
IL (1) IL310975A (es)
MX (1) MX2024002581A (es)
TW (1) TW202310841A (es)
WO (1) WO2023031840A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022121670A1 (zh) 2020-12-10 2022-06-16 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
CN119212708A (zh) * 2022-05-13 2024-12-27 普林斯匹亚生物制药公司 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂
CA3260242A1 (en) * 2022-06-24 2023-12-28 Merck Patent Gmbh TREATMENT REGIMEN FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197080A1 (en) * 2010-08-02 2013-08-01 Sanofi Use of teriflunomide for treating multiple sclerosis
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US12109193B2 (en) * 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
MX2021014157A (es) * 2019-05-23 2022-01-04 Novartis Ag Formas cristalinas de un inhibidor btk.
LT3972603T (lt) 2019-05-23 2024-12-10 Novartis Ag Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių
EP3972604B1 (en) 2019-05-23 2025-06-04 Novartis AG A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
WO2022081512A1 (en) * 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
CA3208277A1 (en) * 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
AU2022231352A1 (en) * 2021-03-03 2023-10-19 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Also Published As

Publication number Publication date
JP2024178420A (ja) 2024-12-24
TW202310841A (zh) 2023-03-16
AU2022337087A1 (en) 2024-03-14
CA3229887A1 (en) 2023-03-09
KR20240055038A (ko) 2024-04-26
JP7564347B2 (ja) 2024-10-08
EP4395779A1 (en) 2024-07-10
IL310975A (en) 2024-04-01
US20240350489A1 (en) 2024-10-24
WO2023031840A1 (en) 2023-03-09
JP2023542878A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
MX2019009443A (es) Metodos para tratar la influenza.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
NI202100047A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE alfa1-ANTITRIPSINA
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.